Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Apr;51(7):737-738.
doi: 10.1111/apt.15634.

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?

Bram Verstockt  1   2 , Marc Ferrante  1   2
Affiliations
Editorial

Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer?

Bram Verstockt et al. Aliment Pharmacol Ther. 2020 Apr.
No abstract available

PubMed Disclaimer

Comment in

Comment on

  • A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
    Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. Dulai PS, et al. Aliment Pharmacol Ther. 2020 Mar;51(5):553-564. doi: 10.1111/apt.15609. Epub 2019 Dec 22. Aliment Pharmacol Ther. 2020. PMID: 31867766 Free PMC article.

References

REFERENCES

    1. Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol. 2020;5:80-92.
    1. Dulai PS, Boland BS, Singh S, et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease. Gastroenterology. 2018;155:687-695 e610.
    1. Dulai PS, Amiot A, Peyrin-Biroulet L, et al. on Behalf of the GETAID OBSERV-IBD, VICTORY Cohorts Collaboration. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020;51:553-564.
    1. Dreesen E, Verstockt B, Bian S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16):1937-1946 e1938.
    1. Yarur AJ, Jain A, Sussman DA, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65:249-255.

Substances

LinkOut - more resources